Posts by John

Explore the latest clinical data on systemic JAK inhibitors for vitiligo. Discover how this emerging treatment works, its efficacy, and vital safety protocols.

Eli Lilly invests $2.8 billion to pioneer psychedelic research, aiming to overcome the limitations of traditional clinical trial infrastructure.

New Phase 1 trial data reveals the safety and potential of iPSC-derived cell therapy to treat subacute spinal cord injuries and promote neural recovery.

Phanes Therapeutics expands its clinical trial with Merck to test Spevatamig alongside KEYTRUDA and chemotherapy for treating biliary tract cancer.

Pharmability gains Swedish MPA approval for a Phase Ib trial of TIR-C, a promising new therapeutic candidate for treating chronic atopic dermatitis.

Mabwell’s bulumtatug fuvedotin shows clinical potential for triple-negative breast cancer patients previously treated with topoisomerase I inhibitors.

New 2-year data confirms 4D-150 gene therapy provides sustained vision improvements for wet AMD patients, potentially reducing the need for recurring injections.

OMEICOS has initiated a Phase 3 trial for OMT-28, a potential breakthrough treatment targeting mitochondrial disease. Learn about this new clinical milestone.

CMS is tightening oversight on RPM vendors. Learn how these regulatory shifts impact data integrity and compliance for clinical trial sponsors.

Explore how the innovative combination of Glofitamab and Englumafusp Alfa is revolutionizing cancer therapy in recent Phase 1 clinical trial findings.